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When conventional treatment of patients with early clinical
reinfarction after thrombolytic therapy fails, mechanical
revascularization may be attempted. An alternative strat-
egy, repeat thrombolytic infusions, is reported. Fifty-two
patients with acute myocardial infarction were treated with
one or two additional thrombolytic infusions of recombi-
nant tissue-type plasminogen activator (rt-PA) because of
nonsustained ischemia after initial treatment with rt-PA or
streptokinase. Thirty-five patients received the second in-
fusion within 1 h of the first; 13 patients received the second
infusion 1 to 72 h after the first and 4 patients received it
later during their hospitalization.
Bleeding complications occurred in 10 patients (19%);
however, most of these were minor (no intracranial bleed-
ing) and only 2 patients required blood transfusion. In 14
Reocclusion of a successfully recanalized infarct-related
artery is a major setback after reperfusion has been achieved
by thrombolytic therapy in patients with acute myocardial
infarction 0,2), The incidence of early reocclusion after
successful reperfusion ranges from 11% to 29% (1-4), Early
reocclusion occurs in up to 45% of successfully treated
patients (3), Treatment of early post-thrombolytic clinical
reinfarction may involve conventional therapy with vasodi-
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patients in whom the decrease in fibrinogen and plasmino-
gen levels was measured after the first and second infusions,
this decrease was only 25% and 63%, respectively-only
slightly higher than the 22% and 53 % decreases measured
in 63 patients who had only one rt·PA infusion. In 44
patients (85%), the acute ischemia resolved completely
within 1 h after initiation of the second infusion. In 23
patients (44%), pain and ST segment elevation did not
recur and invasive coronary intervention was avoided.
Thus, repeat rt-PA infusions can stabilize a substantial
number of patients with acute reinfarction and, even when
relief is temporary, repeat rt·PA infusions can minimize
myocardial damage while patients await mechanical revas-
cularization.
(J Am Coil CardioI1990;16:779-83)
lator and antiplatelet agents and anticoagulant therapy.
When conventional therapy does not resolve the acute
manifestations of myocardial ischemia, a more aggressive
approach with rescue mechanical revascularization may be
attempted. However, not all hospitals are equipped for
interventional cardiology and, in those that are, a 24 h
standby service is often not available. Thus, repeat infusion
of the thrombolytic agent is an additional logical option for
patients who, after the initial administration of a throm-
bolytic agent, have clinical signs of reinfarction that persist
despite full dose medical therapy, Nevertheless, there are
only sporadic reports (5-7) of repeat infusions of recombi-
nant tissue-type plasminogen activator (rt-PA). Although
repeat courses of streptokinase long after the first infusion
have traditionally been regarded as problematic because of
the antigenicity of this agent, a recent report (8) described
0735-1097/90/$3.50
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repeat streptokinase infusions that were successfully admin-
istered within 1 week of the first treatment. However, the
incidence of bleeding among these retreated patients was not
reported.
We report our experience with 52 patients with acute
myocardial infarction who received two to three successive
infusions of 100 to 120 mg rt-PA because of acute recurrence
of nonsustained ischemia after initial treatment with rt-PA or
streptokinase. Although this study does not compare the
effectiveness of repeat rt-PA infusions with other strategies
such as immediate coronary angioplasty, it does evaluate the
clinical outcome and risks associated with successive throm-
bolytic infusions.
Methods
Study patients. Patients were enrolled in two clinical
trials during 1986 through 1989. Twenty-four patients (group
I) were enrolled in a trial that was conducted in the Tel Aviv
area and included a total of 394 patients. An additional 28
patients (group 2) were enrolled more recently during the
International and Gruppo Italiano per 10 Studio della Strep-
tochinasi nell'Infarto Miocardico (GISSI) II rt-PA/STK trial
(9), which included 1,105 patients. Each study protocol was
approved by the institutional Committee on Human Re-
search and all participating patients gave informed consent.
Entry criteria. Eligible patients had severe chest pain for
2:30 min but =:;6 h; ST segment elevation of 2:0.1 mV in two
or more of the limb leads or 2:0.2 mm in one of the precordial
leads (in group I, 0.1 mm in two precordial leads); no left
bundle branch block on the qualifying admission electrocar-
diogram (ECG); and no contraindication to anticoagulant
therapy. Exclusion criteria included oral anticoagulant ther-
apy, recent severe trauma or surgery, past bleeding history
or cerebrovascular accident during the last 6 months.
Thrombolytic protocol. Initial thrombolytic treatment of
patients in group 1 included a 3 to 6 h infusion with a total
dose of 120 mg rt-PA (G 11035. supplied by Boehringer
Ingelheim). Concomitantly, heparin was administered in a
bolus dose of 5,000 lU and followed by continuous infusion
of 25,000 lU/24 h. Aspirin (250 mg) was given daily after the
first 24 h.
Group 2 patients received initial thrombolytic therapy
according to the GISSIIl protocol (9). Patients were there-
fore randomized to receive either a 100 mg rt-PA infusion
administered over 3 h or 1.5 million U streptokinase infused
over 30 to 60 min. Patients in group 2 were further random-
ized to receive or not receive 12.000 Usubcutaneous heparin
twice a day. All patients in this group were treated with 250
mg oral aspirin once daily. beginning immediately after
admission.
Follow-up. All patients stayed in the coronary care unit
for at least the first 24 h after treatment initiation. Serial 12
lead ECG tracings were obtained every few minutes during
the 1st h or until significant resolution of ST segment
elevation was observed (>50% decrease in the baseline sum
of ST elevation) (\0). Successful response to the initial
treatment was defined as rapid resolution of both pain and
sum of ST segment elevation.
Patients who responded to the initial thrombolytic infu-
sion were defined as having recurrent myocardial ischemia
when severe chest pain recurred for 2:30 min and the ST
segment was elevated to a level twice that of the immediate
preischemic level. Thrombolytic infusion was repeated only
after patients failed to respond to conventional therapy with
intravenous heparin, sublingual nifedipine and intravenous
isosorbide dinitrate.
Coagulation variables. Venous blood samples were ob-
tained in the first 14 consecutive patients in group I imme-
diately before infusion of rt-PA and heparin, 10 min after
completion of the initial rt-PA infusion (at approximately 3 to
4 h). immediately before the administration and exactly 10
min after completion of the second infusion. Coagulation
variables were obtained only for patients in group I because
of cost constraints. Plasma levels of fibrinogen and plasmi-
nogen were determined in these samples according to previ-
ously described methods (10).
Results
Baseline characteristics. Fifty-two patients with recurrent
ischemic attacks immediately after thrombolytic therapy for
acute myocardial infarction were treated with repeat throm-
bolytic infusions: 24 belonged to group 1 and 28 to group 2.
There were 43 men and 9 women with a mean age of 55 ± II
and 60 ± II years, respectively. Of the 52 patients, 25 had an
anterior wall and 27 an inferior wall infarction. Time from
onset of symptoms to the initial thrombolytic infusion was
120 ± 45 and 144 ± 63 min in groups I and 2, respectively.
In all 24 patients in group I. rt-PA was the initial throm-
bolytic agent infused. whereas in group 2. 21 patients were
initially treated with rt-PA and 7 initially received streptoki-
nase (Table I).
Patient management and invasive coronary interventions.
Figure I shows the time from completion of the first throm-
bolytic infusion to initiation of the second. Most patients
(n = 35) received the second infusion within I h of comple-
tion of the first. Because of persistently recurring pain and
ST elevation, three patients received a third infusion of
rt-PA (total dose 300 to 360 mg during 12 h) while being
transferred to a tertiary facility for invasive coronary inter-
vention. Two of these patients underwent emergency coro-
nary angioplasty and the other underwent an emergency
coronary bypass operation while still receiving the rt-PA
infusion. Forty-four of the 52 patients responded to the
repeat thrombolytic infusion with significant resolution of
pain and ST elevation 10 to 50 min after initiation of the
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Table 1. Bleeding Complications and Revascularization Procedures in 52 Patients by Treatment Group
Coronary Angioplasty
Initial Second
Incidence of Emergency
Thrombolytic Thrombolytic
Bleeding Total Emergency Bypass Surgery Death
No. Infusion Infusion No. (%) No. (%) No. (%) No. (%) No.
Group I
24 rt-PA 120 mg/3 h rt-PA 120 mg/3 h (12.5) II (46) 8 (33) (12.5)
Group 2
22 rt-PA 100 mg/3 h rt-PA 100 mg/3 h (23) (23) (4.5)
6 SK 1.5 million U rt-PA 100 mg/3 h 2 (33)
Total
52 10 (19) 15 (29) 9 (17) (6) 2 (4)
rt-PA = recombinant tissue-type plasminogen activator: SK = streptokinase.
second protocol. In 33 of these 44 patients, this resolution
occurred within 20 min of initiation of the second infusion.
In 23 (44%) of the 52 patients, pain and ST elevation
completedly resolved after the second rt-PA infusion and
coronary angiography was therefore not performed. In 29
patients, pain and ST elevation recurred after the second
infusion was completed. These 29 patients underwent coro-
nary angiography during hospitalization and, in 15 of them,
coronary angiography and angioplasty were performed on an
emergency basis. Of the 29 patients in whom coronary
angiography was performed after repeat thrombolytic infu-
sions, 16 (55%) had single vessel disease, 10 (34%) had
double vessel disease and 3 00%) had triple vessel disease.
The infarct-related artery was the left anterior descending
artery in 14 (48%), the right coronary artery in 11 (38%) and
the circumflex artery in 4 04%). Angiography in the 29
patients revealed an occluded infarct-related artery in 11,
high grade stenosis of :::::90% in 11. stenosis of 70% to 90% in
5 and stenosis of :;50% in 2.
All three of the patients who had an emergency coronary
artery bypass procedure had the operation within 12 h of
completion of the second rt-PA infusion. No excessive
bleeding was noted in these patients.
Follow-up. During hospitalization. two patients died of
cardiogenic shock after reinfarction that occurred 5 hand 3
days after admission. respectively, and did not clinically
respond to the repeat thrombolytic infusion. During the
follow-up period (on average 19 ± 10 months), seven pa-
tients (\8%) required rehospitalization for cardiac reasons.
Three of these had reinfarction and one of them died within
2 months of admission.
Bleeding complications. Bleeding was observed in 10
(\9%) of the 52 patients; however. most bleeding complica-
tions were minor and only 2 patients required blood trans-
fusion (Table 2). Bleeding complications were evenly distrib-
uted among patients who were retreated within 1h and those
treated a few days after completion of the first thrombolytic
infusion. There was no intracranial bleeding.
Table 3 shows the change in fibrinogen and plasminogen
plasma levels from before treatment through completion of
the initial and repeated thrombolytic infusions. After com-
pletion of the second rt-PA infusion, fibrinogen and plasmi-
nogen decreases were only slightly more accentuated com-
pared with those in an additional 63 patients with acute
myocardial infarction who belonged to the same clinical trial
as group 1 patients but who had only one rt-PA infusion.
TIme Interval Between Thrombolytic infusions
Figure 1. Distribution of patients and bleeding complications by
time interval between thrombolytic infusions.
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Discussion
Indications for repeat thrombolytic infusions. The deci-
sion to repeat infusions of thrombolytic agents soon after
completion of the initial thrombolytic infusion should weigh
the increased risk of bleeding that may be associated with
the higher total fibrinolytic dose against the risk of further
myocardial damage. In most of our patients. repeat rt-PA
infusions with the standard initial bolus dose and increased
1st h dose rapidly relieved myocardial ischemia and signifi-
cantly resolved recurring chest pain and ST segment eleva-
tion. It is also noteworthy that in a substantial proportion of
our patients (23 [44%] of 52), the acute manifestations of
myocardial ischemia completely resolved after the second
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Table 2. Ten Patients With Bleeding Complications After Repeat Thrombolytic Infusions
Time
Patient Age lyO,' Interval
No. Gender Initial Infusion Repeat Infusion (h) Source of Bleeding
42/M rt-PA 120 mg/3 h rt-PA 120 mg/3 h <I h Hematemesis
2 70/M rt-PA 120 mg/3 h rt-PA 120 mg/3 h 72h Hematemesis
3 6I1F rt-PA 120 mg/3 h rt-PA 120 mg/3 h 72h Cath access site
4 70/F rt-PA 100 mg/3 h rt-PA 100 mg/3 h <I h Hematemesis
5 67/M rt-PA 100 mg/3 h rt-PA 100 mg/3 h 72h Hematuria
6 62/F rt-PA 100 mg/3 h rt-PA 100 mg/3 h <I h IV access site*
7 60/M rt-PA 100 mg/3 h rt-PA 100 mg/3 h <I h IV access site
8 78/M rt-PA 100 mg/3 h rt-PA 100 mg/3 h 5 h Melena and hematemesis
9 60/M SK 1.5 million U rt-PA 100 mg/3 h <I h Hematemesis
10 77/M SK 1.5 million U rt-PA 100 mg/3 h 2 h Unknownt
Blood
Transfusion
IU
3 U
'Patient received three infusions of 100 mg of rt-PA over 12 h. Bleeding was observed at tbe end of the second infusion: however. the infusion could not be
terminated because of rapid hemodynamic deterioration. Successful emergency coronary angioplasty was performed. tDecrease of 2 g in hemoglobin without
overt bleeding. Cath = catheterization: F = female: IV = intravenous: M = male: other abbreviations as in Table I.
thrombolytic infusion and invasive coronary intervention
was avoided.
Repeat administration of rt-PA may also he helpfiil in
patients in whom IIrRe/lt coronary interl'ention is required
hilt cannot he pe/formed immediately. The recent report of
the Thrombolysis in Myocardial Infarction. Phase lIB (TIMI
lIB) trial (\ I) recommended a conservative "watchful wait-
ing" strategy that can be accomplished in hospitals without
catheterization facilities. This strategy requires that unstable
patients be transferred to tertiary hospitals where definitive
mechanical revascularization can be performed. However.
while waiting for catheterization. patients with acute and
nonsustained myocardial ischemia may incur additional
myocardial injury. Repeat rt-PA infusions may serve to
minimize myocardial damage until intervention is feasible. It
also seems that bleeding complications are less of a problem
with repeat rt-PA infusions when stable clinical reperfusion
is not achieved and emergency mechanical revascularization
is indicated. Of the 15 patients who underwent emergency
coronary angioplasty immediately after repeat rt-PA infu-
sions. only I had a minor bleeding complication. Two of our
patients had an emergency coronary bypass operation im-
mediately after repeat rt-PA infusions and a third patient had
a bypass procedure while receiving his third successive
rt-PA infusion: none of these patients had excess bleeding.
Bleeding complications. Repeat thrombolytic infusions
were associated with an increase in bleeding complications.
The 19C/r incidence rate of bleeding in our group of 52
patients was higher than the 5.5C/r rate experienced by the
rest of the group I study patients or the 69c rate in the rest of
group 2 patients. However. most bleeding complications
were minor and only two of the retreated patients required
blood transfusion. Although emergency coronary interven-
tions were performed in 8 patients immediately after the
second or third rt-PA infusion. only I of the 52 reported
patients had catheterization site bleeding. We do not have an
explanation for this lower incidence of bleeding from the
catheterization site compared with that in earlier reports
(4.12.13) in which such bleeding was more frequent (\ 9% to
427r). However. it seems that the risk of bleeding associated
Table 3. Fibrinolytic Variables in 14 Patients With Acute Myocardial Infarction Treated With Repeat rt-PA Infusion*
'Ii Decrease
Baseline End of From Baseline
Level Protocol I Level
Fibrinogen (mg/dl)t
Control 385 ± 78 302 ± 76 21.5
Early repeat rt-PA 360 ± 36 301 ± 48 16.3
Late repeat rt-PA 371 ± 65 317 ± 55 14.5
Plasminogen IU/dl)t
Control 91 ± 15 43 ± 15 50.5
Early repeat rt-PA 108 ± 15 46 ± 8 57.4
Late repeat rt-PA 86 ± 27 37 ± 7 56.9
Start of
Protocol 2
293 ± 36
421 ± 87
58 ± 18
85 ± 29
End of
Protocol 2
304 ± 84
377 ± 103
39 ± 9
35 ± 3
'7c Decrease
From Baseline
Level
16
53
64
59
*General group of 63 control patients treated with single rt-PA infusion 1120 mg/6 h): 10 patients treated with a second rt-PA infusion within I h of completion
of the first 1240 mg/6 to 8 h: 4 patients treated with a second rt-PA infusion n h after completion of the first infusion (each infusion 120 mg/3 to 6 hi. tNormal
range: fibrinogen 190 to 470 mg/dl: plasminogen 63 to 118 U/dl. rt-PA = recombinant tissue-type plasminogen activator.
JACC Vol. In, No.4
October 1990:779-X3
BARBASH ET AL.
REPEAT INFUSIONS OF RT-PA
783
with repeat rt-PA infusion only slightly exceeds the risk
involved with the first infusion.
Fibrinogen levels. After completion of the second infu-
sion, fibrinogen levels decreased only 16% below baseline. a
decrease similar to that observed in patients treated accord-
ing to the regular 100 to 120 mg rt-PA protocol. However.
the decrease in fibrinogen blood levels caused by rt-PA may
be attenuated by two different mechanisms: I) fibrinogen
blood levels after the second rt-PA infusion were measured
10 to 12 h after the onset of infarction when an increase in
fibrinogen as an acute phase reactant could be expected: and
2) plasminogen breakdown during the second rt-PA infusion
was less than that observed during the first rt-PA infusion (19
versus 50 U/dll (Table 3). As a result. smaller amounts of
plasmin were available and less fibrinogenolysis could thus
be expected. Also. the decrease in plasminogen blood level
was similar to that observed after a single rt-PA infusion.
Conclusions. Repeat rt-PA administration does not en-
sure stable myocardial perfusion. In some patients, myocar-
dial ischemia may recur after circulating plasma rt-PA levels
decrease (7). For a significant proportion of patients. how-
ever, repeat thrombolytic infusion may lead to a stable
hemodynamic situation. Also, the long-term outcome of
these patients indicates the importance of repeat rt-PA
infusions as an alternative strategy. Although our experience
is based on a relatively small number of patients. we believe
that in some patients with early reinfarction, the increased
risk of bleeding is outweighed by the risk of further progres-
sion of myocardial infarction. Thus, repeat administration of
rt-PA is an option to be considered in patients with signifi-
cant recurrent acute myocardial ischemia that does not
resolve with conventional medical therapy. When neces-
sary, repeat rt-PA infusion may be used to buy time until
mechanical revascularization can be performed. This is
especially important in institutions without round the clock
interventional cardiology or when the patient must be trans-
ferred to a tertiary facility for mechanical revascularization.
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